First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch ...
CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
Xeris Pharmaceuticals announced the launch of Gvoke HypoPen™ (glucagon) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older. Xeris ...
Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
Approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen at launch Easy to use: premixed and ready-to-go A reliable method of delivery: 99% of people were ...
SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch and availability of Gvoke VialDx™ (glucagon injection). Gvoke VialDx (glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback